Found: 10
Select item for more details and to access through your institution.
The ATR inhibitor elimusertib exhibits anti‐lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 1, p. 191, doi. 10.1111/bjh.19218
- By:
- Publication type:
- Article
In vitro anti‐lymphoma activity of the first‐in‐class pan‐NOTCH transcription inhibitor CB‐103.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 5, p. 669, doi. 10.1111/bjh.18576
- By:
- Publication type:
- Article
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP‐319 in pre‐clinical models of aggressive lymphomas.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 5, p. 595, doi. 10.1111/bjh.16118
- By:
- Publication type:
- Article
Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma.
- Published in:
- British Journal of Haematology, 2019, v. 184, n. 6, p. 1022, doi. 10.1111/bjh.15212
- By:
- Publication type:
- Article
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 6, p. 936, doi. 10.1111/bjh.14803
- By:
- Publication type:
- Article
Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 2, p. 399, doi. 10.3390/jcm12020399
- By:
- Publication type:
- Article
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax.
- Published in:
- Cancers, 2019, v. 11, n. 6, p. 775, doi. 10.3390/cancers11060775
- By:
- Publication type:
- Article
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes.
- Published in:
- Marine Drugs, 2020, v. 18, n. 12, p. 619, doi. 10.3390/md18120619
- By:
- Publication type:
- Article
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma.
- Published in:
- EJHaem, 2022, v. 3, n. 3, p. 764, doi. 10.1002/jha2.535
- By:
- Publication type:
- Article
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-020-20820-x
- By:
- Publication type:
- Article